Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts

Last Updated: December 12, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for RTA 744

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for RTA 744?

RTA 744 is an investigational drug.

There have been 4 clinical trials for RTA 744. The most recent clinical trial was a Phase 1 trial, which was initiated on October 1st 2007.

The most common disease conditions in clinical trials are Meningitis, Meningeal Carcinomatosis, and Brain Neoplasms. The leading clinical trial sponsors are Reata Pharmaceuticals, Inc., M.D. Anderson Cancer Center, and [disabled in preview].

Recent Clinical Trials for RTA 744
RTA 744 in Breast Cancer Patients With Progression of Previously Irradiated Brain MetastasesReata Pharmaceuticals, Inc.Phase 2
A Safety Study of RTA 744 in Recurrent, Progressive or Refractory Neoplastic MeningitisReata Pharmaceuticals, Inc.Phase 1
RTA 744 Injection in Patients With Leptomeningeal DiseaseReata Pharmaceuticals, Inc.Phase 1

See all RTA 744 clinical trials

Clinical Trial Summary for RTA 744

Top disease conditions for RTA 744
Top clinical trial sponsors for RTA 744

See all RTA 744 clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.